MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-07-2022
AVEO Pharmaceuticals DSO Ratio 2011-2026 | AVEO
Annual DSO Ratio AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 47.5 | 72.6 | 20.7 | 204 | 19.4 | 149 | 89 | 47.1 | 1.92 K | 391 | 16 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.92 K | 16 | 271 |
Quarterly DSO Ratio AVEO Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 28.1 | - | 49.6 | 46.8 | 37.7 | 32.4 | 27.2 | - | 2.76 | 5.49 | 6.45 | 195 | 5.79 | 212 | 132 | 186 | 112 | 638 | 152 | 447 | 7.95 | 105 | 25.8 | 738 | 94.5 | 486 | 215 | 118 | 27.9 | 3.16 K | 2.38 K | 1.86 K | 245 | 116 | 9.92 | 278 | 278 | 277 | 3.06 K | 121 | 1.85 K | 1 K | 1.48 K | 600 | 184 | 24.8 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.16 K | 2.76 | 478 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.35 | 0.72 % | $ 3.7 B | USA |
 |
Galapagos NV
GLPG
|
56.5 | $ 28.39 | -0.13 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.5 | 5.42 % | $ 5.76 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 23.42 | -0.3 % | $ 2.98 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 52.38 | -2.24 % | $ 4.71 B |  Schweiz |
 |
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.64 | 4.46 % | $ 436 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Фармсинтез
LIFE
|
209 | - | - | - |  Russia |